Bioventus Inc.

NasdaqGS:BVS Aktierapport

Börsvärde: US$843.4m

Bioventus Framtida tillväxt

Future kriterier kontrolleras 2/6

Bioventus förväntas öka vinsten och intäkterna med 18% och 6.4% per år respektive medan EPS förväntas växa med 16.3% per år.

Viktig information

18.0%

Tillväxttakt i vinsten

16.27%

Tillväxttakt för EPS

Medical Equipment vinsttillväxt16.0%
Intäkternas tillväxttakt6.4%
Framtida avkastning på eget kapitaln/a
Bevakning av analytiker

Low

Senast uppdaterad16 Apr 2026

Senaste uppdateringarna om framtida tillväxt

Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 09
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside

Analysts have maintained their Bioventus fair value estimate at $14.80 while making only small adjustments to key inputs such as the discount rate and expected future P/E, indicating fine-tuning of their valuation framework rather than a major change in outlook. What's in the News Bioventus Inc.

BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside

Analysts have modestly fine tuned their $14.80 price target for Bioventus, keeping it steady overall as minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions leave the valuation view essentially unchanged. What's in the News Bioventus Inc.

BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside

Analysts have revised their price target for Bioventus slightly lower from $15.00 to $14.80, reflecting updated fair value and discount rate assumptions while maintaining similar views on revenue growth, profit margin and future P/E expectations. What's in the News Bioventus Inc.

BVS: 2026 Net Sales Guidance And Margin Outlook Will Support Further Upside

Analysts have adjusted their price target on Bioventus to $15.00 from $14.50, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that collectively support a slightly higher valuation. What's in the News Bioventus issued earnings guidance for 2026, setting expected net sales in a range of $600 million to $610 million.

BVS: Refined Assumptions And 2026 Outlook Will Support Further Upside Potential

Analysts have adjusted their price target on Bioventus slightly lower from $15.00 to $14.50, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News Bioventus issued earnings guidance for 2026, with expected net sales of $600 million to $610 million.

BVS: Higher Revenue Outlook And Richer Future P/E Will Drive Upside

Analysts have revised their Bioventus price target to $13.00 from $7.00, reflecting updated views on fair value, discount rate assumptions, revenue growth expectations, profit margin outlook and future P/E multiples. Valuation Changes Fair Value: revised to $13.00 from $7.00, indicating a higher assessed equity value per share.

BVS: Fine Tuned Assumptions Will Support Further Upside Potential

Analysts have nudged their price target on Bioventus to US$15.00, a modest change that reflects fine tuning to inputs such as the discount rate, long term revenue growth, profit margin assumptions, and expected future P/E rather than a shift in their overall view of the company. Valuation Changes Fair Value: Maintained at US$15.00 per share, with no change in the overall valuation output.

BVS: Reaffirmed 2025 Guidance And Stable Assumptions Will Support Further Upside

Analysts have kept their fair value estimate for Bioventus unchanged at US$15.00, with only slight tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This signals a broadly steady view of the stock's risk and return profile.

BVS: Reaffirmed 2025 Guidance Will Support Ongoing Upside Potential

Analysts have kept their fair value estimate for Bioventus steady at US$15.00, citing only very small tweaks to inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions that do not materially change their overall view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2025, signaling no change to its previously communicated outlook.

BVS: Reaffirmed 2025 Earnings Guidance Will Support Continued Upside Potential

Analysts have nudged their price target on Bioventus slightly higher to reflect modestly stronger revenue growth expectations and a marginally lower discount rate, while keeping fair value unchanged at approximately $15.00 per share. What's in the News Bioventus reaffirmed its full year 2025 earnings guidance, signaling management confidence in the current strategic and operating plan (company guidance).

BVS: Earnings Guidance Will Support Continued Upside Potential In Shares

Analysts have modestly raised their price target on Bioventus to approximately $15.00 per share from about $15.00 per share, reflecting slightly lower perceived risk, stable long term growth expectations, and marginally improved profitability and valuation assumptions. What's in the News Bioventus reaffirmed its 2025 earnings guidance, projecting net sales between $560 million and $570 million.

Bioventus: A New Start

Dec 02

Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly

Nov 26
Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly

BVS: Earnings Guidance Is Expected To Drive Share Price Higher

Analysts have updated their price target for Bioventus, raising it modestly from $14.67 to $15.00 per share. This change reflects improved revenue growth expectations, despite a slightly higher discount rate and lower projected profit margin.

BVS: Net Sales Guidance Will Sustain Bullish Outlook Into 2025

Analysts have slightly raised their price target for Bioventus to $14.67 per share, citing minor updates to the company's discount rate and future price-to-earnings assumptions. What's in the News Bioventus Inc.

Minimally Invasive Nonopioid Pain Management Will Expand With PNS

Analysts have modestly raised their price target for Bioventus, increasing it by $0.00 to $14.67. They cited slight adjustments to their discount rate and future price-to-earnings assumptions.

Minimally Invasive Nonopioid Pain Management Will Expand With PNS

Analysts have raised their price target for Bioventus from $12.75 to approximately $14.67 per share, citing improvements in projected revenue growth and a more favorable future price-to-earnings outlook. What's in the News Bioventus issued new earnings guidance for 2025 and estimates net sales between $560 million and $570 million.

We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative

Aug 14
We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative

Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 09
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next
User avatar

Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets

Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.

Is Bioventus (NASDAQ:BVS) Using Too Much Debt?

May 07
Is Bioventus (NASDAQ:BVS) Using Too Much Debt?

Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues

Mar 08
Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues

Bioventus: Amply Rewarded For Recent Progress

Jan 05

Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024

Aug 12

Bioventus: Bullish On Path To Profitability

Jan 24

Prognoser för vinst- och omsättningstillväxt

NasdaqGS:BVS - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/20286874596922
12/31/20276464386905
12/31/20266053381845
12/31/2025568237275N/A
9/27/2025564105356N/A
6/28/202556423436N/A
3/29/2025568-312425N/A
12/31/2024573-363739N/A
9/28/2024555-422830N/A
6/29/2024537-44811N/A
3/30/2024523-2227N/A
12/31/2023512-97815N/A
9/30/2023503-104010N/A
7/1/2023511-169818N/A
4/1/2023514-173-110N/A
12/31/2022512-104-25-14N/A
10/1/2022517-91-15-6N/A
7/2/2022497-19-46N/A
4/2/2022466-161120N/A
12/31/2021431-5923N/A
10/2/2021399-32935N/A
7/3/202137664046N/A
4/3/202132443136N/A
12/31/2020321165572N/A
9/26/2020320167167N/A
6/27/2020316126258N/A
3/28/2020339155554N/A
12/31/201934093841N/A
12/31/2018319-1N/A45N/A
4/2/2016266-23N/A25N/A
12/31/2015254-38N/A19N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: BVS s prognostiserade vinsttillväxt ( 18% per år) är över sparkvoten ( 3.4% ).

Resultat vs marknad: BVS s intäkter ( 18% per år) förväntas växa snabbare än marknaden för US ( 16% per år).

Höga tillväxtresultat: BVS s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: BVS s intäkter ( 6.4% per år) förväntas växa långsammare än marknaden för US ( 11.1% per år).

Hög tillväxtintäkter: BVS s intäkter ( 6.4% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: Otillräcklig data för att avgöra om BVS s avkastning på eget kapital förväntas bli hög om tre år

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/03 01:17
Aktiekurs vid dagens slut2026/05/01 00:00
Intäkter2025/12/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Bioventus Inc. bevakas av 10 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Michael PetuskyBarrington Research Associates, Inc.
Kyle RoseCanaccord Genuity
Caitlin CroninCanaccord Genuity